Kestrel Therapeutics Gains FDA Fast Track for KST-6051
WATERTOWN, Mass. — September 15, 2026 Kestrel Therapeutics Inc. announced that the U.S. Food and Drug Administration (FDA) has...
solid tumors
Advertisement
Nanobiotix Advances JNJ-1900 in Recurrent NSCLC
PARIS, France and CAMBRIDGE, Mass. — September 14, 2026 Nanobiotix announced complete Phase 1 safety and efficacy findings for...
Revolution Medicines Gains FDA Breakthrough Designation for RASONQUE
REDWOOD CITY, Calif. — September 14, 2026 Revolution Medicines, Inc. announced that the U.S. Food and Drug Administration (FDA)...
IMUNON and NCI Advance IMNN-001 Clinical Development
LAWRENCEVILLE, N.J. — September 10, 2026 IMUNON, Inc. announced a Cooperative Research and Development Agreement (CRADA) with the National...
Lyell Immunopharma Completes LYL273 Manufacturing Transfer
SOUTH SAN FRANCISCO, Calif. — September 10, 2026 Lyell Immunopharma, Inc. announced the successful completion of the planned technology...
Advertisements
Crossbow Therapeutics Doses First Patient in CBX-663 Phase 1
CAMBRIDGE, Mass. — September 9, 2026 Crossbow Therapeutics, Inc. announced dosing of the first participant in the Phase 1...
CU Anschutz Wins FDA Clearance for CAR T Cancer Trial
Aurora, Colorado, U.S., September 10, 2026 University of Colorado Anschutz Medical Campus (CU Anschutz) has received U.S. Food and...
TwoStep Therapeutics Secures $62.5M and FDA IND Clearance
SAN CARLOS, Calif. — September 9, 2026 TwoStep Therapeutics announced an oversubscribed $62.5 million Series A financing alongside U.S....
1cBio and Lee’s Pharm Partner on PARP1 Inhibitor OC-3
San Francisco, California, and Hong Kong, China, September 9, 2026 1cBio and Lee’s Pharmaceutical Holdings Limited (Lee’s Pharm) have...
Harbour BioMed Partner Solstice Oncology Raises $225M
Shanghai, China, September 10, 2026 Solstice Oncology, a partner of Harbour BioMed, has announced a $225 million Series A...
Advertisement
